微RNA的表达谱血清和HBsAg颗粒的初步研究：治疗性疫苗效力的

StephenW

Medicine (Baltimore). 2016 Jan;95(2):e2511.
A Pilot Study of MicroRNAs Expression Profile in Serum and HBsAg Particles: Predictors of Therapeutic Vaccine Efficacy in Chronic Hepatitis B Patients.Wang W1, Li J, Zhang X, Wen Y, Wang XY, Yuan Z.
Author information

• 1From the Key Laboratory of Medical Molecular Virology (WW, JL, YW, X-YW, ZY), School of Basic Medical Sciences, Shanghai Medical College, Fudan University; and Shanghai Public Health Clinical Center University (WW, JL, XZ), Key Laboratory of Medical Molecular Virology, Shanghai Medical College, Fudan University, Shanghai, China.
  

AbstractChronic hepatitis B (CHB) remains a global health problem. Therapeutic vaccination has been successfully employed to treat a subpopulation of CHB patients. Personalized treatment can not only improve therapeutic efficacy, but also decrease the cost of medical care. Since microRNAs (miRNAs) are highly conserved and are involved in many cellular processes, exploring their expression profiles in CHB patients in association with responsiveness to therapeutic vaccination may be an approach for personalized treatment. In this study, we examined the kinetic expression profiles of 13 miRNAs in sera and serum-derived hepatitis surface antigen (HBsAg) particles in 10 CHB patients including 5 responders and 5 nonresponders selected from a large cohort of 136 patients enroled in a phase III clinical trial using antigen-antibody immunogenic complex based therapeutic vaccine (YIC). Eight miRNAs were detected in both sera and HBsAg particles. Among them, the levels of serum miRNAs and serum-derived HBsAg-carried miRNAs (let-7f, miR-22, miR-30a, and miR-122) were significantly lower in the responders group compared to those in the nonresponders group at baseline and throughout the course of treatment. The lower baseline levels of serum miRNAs and HBsAg-carried miRNAs were also associated with hepatitis e antigen clearance at week 76 and hepatitis e antigen seroconversion during the study period. In summary, our study suggests that lower baseline levels of serum miRNAs and HBsAg-carried miRNAs (let-7f, miR-22, miR-30a, and miR-122) associated with YIC treatment response and the variation trend of these 4 miRNAs could have a prognostic value for responsiveness to YIC treatment.


PMID:26765470 [PubMed - as supplied by publisher]

StephenW

医学（巴尔的摩）。 2016月; 95（2）：e2511。
微RNA的表达谱血清和HBsAg颗粒的初步研究：治疗性疫苗效力的慢性乙型肝炎患者预测。
王W1，李江，张新，文Y，王晓燕，袁Z.
作者信息从医学分子病毒学复旦大学重点实验室（WW，JL，YW，X-YW，ZY），基础医学科学学院，上海医学院;和上海公共卫生临床中心大学（WW，JL，XZ），医学分子病毒学，上海医学院，复旦大学，上海，中国的重点实验室。
抽象
慢性乙型肝炎（CHB）仍然是一个全球性的健康问题。治疗性疫苗接种已被成功地用于治疗慢性乙型肝炎患者的亚群。个性化的治疗，不仅可以提高治疗功效，同时也降低医疗成本。因为微RNA（miRNA）是高度保守的，并参与许多细胞过程，在与响应性治疗性疫苗接种的关联探索慢性乙型肝炎患者的表达谱可以是用于个性化的治疗的方法。在这项研究中，我们血清和血浆源性乙肝表面抗原（HBsAg）颗粒审查了10例慢性乙型肝炎患者，包括5反应和5个无反应者136例enroled一个阶段的大样本选择的13个miRNA的动能表达谱III期临床试验使用抗原 - 抗体的免疫原性复合物基于治疗性疫苗（YIC）。在这两种血清和HBsAg颗粒进行检测八的miRNA。其中，血清miRNAs与血清衍生的HBsAg携带miRNA的水平（让-7F中，miR-22中，miR-30a中，和miR-122）均显著降低在反应者组相比，那些在无反应者组在基线并在整个治疗过程中。血清中的miRNA和乙肝表面抗原携带miRNA的低基线水平还分别与乙肝e抗原清除率在研究期间，相关的76周和戊型肝炎抗原血清学转换。总之，我们的研究表明，血清的miRNA与HBsAg携带的miRNA（让-7F中，miR-22中，miR-30a中，和miR-122）与YIC治疗反应和这些4 miRNA的变化趋势相关联的较低基准水平可以对反应能力YIC治疗预后价值。
结论：26765470 [考研 - 由发行商提供]